Hemab Therapeutics (COAG)
Develops preventive therapies for rare bleeding and coagulation disorders.
$44.11
Pre-market−0.54 (−1.21%)
At close$44.65(+1.43%)
In millions of USD, except per-share figures
| In millions | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|
| Cost of revenue | 0 | 0 |
| Gross profit | 0 | 0 |
| 24 | 26 | |
| Research & development | 19 | 20 |
| 4 | 6 | |
| General & administrative | 4 | 6 |
| Operating income | −24 | −26 |
| 1 | 2 | |
| Interest income | 1 | 3 |
| Income before tax | −23 | −24 |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | −23 | −24 |
| Net income | −23 | −24 |
| EPS, basic | −$0.51 | −$0.80 |
| EPS, diluted | −$0.51 | −$0.80 |
| Weighted average shares, basic | 44 | 30 |
| Weighted average shares, diluted | 44 | 30 |
| EBITDA | −24 | −26 |
| Depreciation & amortization | 0 | 0 |
| EBIT | −24 | −26 |